Early Lumbar Drainage for Intraventricular Hemorrhage
Key facts
- Who runs it
- Second Affiliated Hospital of Nanchang University
- Where
- China31 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT07625449
- CHICTR2600123877
- Status
- Not yet recruiting
- People taking part
- 392 people, planned
- Started
- Oct 2026
- Expected to end
- Oct 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Control treatment plus lumbar drainage
- Control treatment schedule
- Record updated
- 4 September 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Aged 18-85 years, of either sex
- First-ever intracerebral hemorrhage (ICH) with CT-confirmed hemorrhage involving the third and/or fourth ventricle, and scheduled to undergo or already having undergone burr-hole ventricular drainage
- Intraparenchymal hemorrhage volume <30 mL on admission CT, with stable neurological status and no progressive deterioration before randomization
- Randomization completed within 72 hours of symptom onset
- Pre-onset modified Rankin Scale (mRS) score of 0 (no symptoms) or 1 (minor symptoms not interfering with daily activities)
- Written informed consent obtained from the participant or a legal guardian
Who cannot take part
- Participation in another interventional clinical trial within 30 days before randomization
- Secondary intracerebral hemorrhage, including imaging-confirmed untreated intracranial arteriovenous malformation (AVM), ruptured intracranial aneurysm, moyamoya disease, or intracranial tumor
- Long-term use of anticoagulant medication, persistent coagulopathy, or known allergy to urokinase
- Absolute contraindications to lumbar or external ventricular drainage (e.g., cerebral herniation, infection at the puncture site)
- Infratentorial hemorrhage with a volume ≥10 mL
- Thalamic hemorrhage with a volume ≥10 mL, or accompanied by obvious extension into the midbrain, oculomotor nerve palsy, or fixed and dilated non-reactive pupils
- Active bleeding from other sites, including the gastrointestinal, genitourinary, or respiratory tracts
- Multiple superficial ecchymoses, purpura, or other signs suggesting bleeding or a bleeding tendency
- Other coexisting severe diseases that are difficult to treat
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study
- Prothrombin time (PT) or activated partial thromboplastin time (APTT) prolonged to more than twice the upper limit of normal
- Unilateral limb paralysis (muscle strength grade 0 or 1) before randomization
- Expected survival of less than 6 months due to other causes
- Pregnancy
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial in Chinese patients with intraventricular hemorrhage (IVH), comparing early lumbar drainage added to standard care with standard care alone. The primary objective is to evaluate whether, in patients treated with external ventricular drainage (EVD) and intrathecal urokinase, the addition of early lumbar drainage improves functional outcomes at 180 days, as measured by the modified Rankin Scale (mRS), and reduces complications.
The 2 groups in the trial
- Control Group (EVD + Intrathecal Urokinase)Existing treatment, for comparison
Patients received external ventricular drainage (EVD) combined with intrathecal urokinase injection. Urokinase was administered as a single daily dose of 30,000 IU for 3 consecutive days. A follow-up cranial CT was then performed to assess ventricular obstruction and hematoma clearance, which guided the decision on whether to continue thrombolysis. The maximum total duration of urokinase treatment did not exceed 5 days. Thrombolysis was discontinued when CT demonstrated clearance of the third/fourth ventricular cast, relief of mass effect, or a hematoma clearance rate of ≥80%.
Treatment: Control treatment schedule
- Intervention Group (Control Treatment + Lumbar Drainage)Treatment being tested
In addition to the same EVD and intrathecal urokinase regimen as the control group, early lumbar drainage was initiated within 72 hours of onset. The CSF drainage rate was maintained below 8 mL/h, and the daily total drainage volume did not exceed 200 mL to maintain stable intracranial pressure.
Treatment: Control treatment plus lumbar drainage
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effectiveness and Safety of Early Lumbar Drainage in the Treatment of Ventricular Hemorrhage: the LD-IVH Randomized Controlled Trial
- Criteria questions
- Built from NCT07625449, who can take part
- Record updated
- 4 September 2026